Podcasts about gp100

GOD Provides / JESUS SavesPatreon https://bit.ly/3jcLDuZServant MilitoBecome a supporter of this podcast: https://www.spreaker.com/podcast/gunfighter-life-survival-guns-tactical-hunting--4187306/support.

Cumplimos 100 programas gracias a vuestro apoyo y compañía, estamos preparando un 2025 espectacular y que pronto podreis vernos en youtube y en twitch, en este episodio hablamos de difertentes noticias de diferentes categorias. Con Chema Rodriguez, David Castañeda y Lucas Ambit Muchas gracias por estar ahi y nos vemos en el programa GP101 el dia 14 de Enero con invitados. Síguenos en instagram @goma_quemada_motorsport y en las app de Ivoox, spotify, itunes y googlepodcast. ¡¡ Feliz Navidad !! y ¡¡ Feliz Año 2025 !!

Dr. Ryan Augustin and Dr. Jason Luke discuss neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, promising new TIL therapy for advanced melanoma, and the emerging role of CD3 engagers in treatment strategies. TRANSCRIPT Dr. Ryan Augustin: Hello, I'm Dr. Ryan Augustin, your guest host of the ASCO Daily News Podcast today. I'm a medical oncology fellow at Mayo Clinic in Rochester, Minnesota. Joining me today is Dr. Jason Luke, an associate professor of medicine and the director of the Cancer Immunotherapeutic Center at the University of Pittsburgh Hillman Cancer Center. I had the privilege of working as a postdoc in Jason's translational bioinformatics lab, where we investigated mechanisms of resistance to immunotherapy in melanoma and other cancers.  Today, we'll be discussing 3 important topics, including neoadjuvant immunotherapy and the importance of multidisciplinary team coordination, the impact and practical considerations for incorporating TIL therapy into melanoma, and the current and future use of CD3 engagers in both uveal and cutaneous melanoma.  You'll find our full disclosures in the transcript of this episode.  Jason, it's great to have this opportunity to speak with you today. Dr. Jason Luke: Absolutely. Thanks, Ryan. It's great to see you. Dr. Ryan Augustin: So, to kick things off, Jason, we, of course, have seen tremendous advances in cancer immunotherapy, not only in metastatic disease but also the perioperative setting. Recent data have shown that the use of neoadjuvant therapy can provide not only critical prognostic information but can also help individualize post-resection treatment strategies and potentially even eliminate adjuvant therapy altogether in patients who achieve a pathologic, complete response. This signifies a conceptual shift in oncology with the goal of curing patients with immunotherapy. In triple-negative breast cancer, the KEYNOTE-522 regimen with pembrolizumab is standard of care. In non-small cell lung cancer, there are now four FDA approved chemo-IO regimens in both the neoadjuvant and perioperative settings. And, of course, in melanoma, starting with SWOG S1801 utilizing pembro mono therapy, and now with combined CTLA-4 PD-1 blockade based on results from the NADINA trial, neoadjuvant IO is the new standard of care in high-risk, resectable melanoma. It's important to highlight this because whereas other tumor types have more mature multidisciplinary care, for example, patients with breast cancer are reviewed by the whole team in every center, and every patient with lung cancer certainly benefits from multidisciplinary care conferences, that's not always the case with melanoma, given the relative frequency of cases compared to other tumor types.  Jason, would you say that we have now moved into an era where the integration of a multidisciplinary team and melanoma needs to be prioritized. And why is it important to have multidisciplinary team coordination from the onset of a patient's diagnosis? Dr. Jason Luke: Well, I think those are great questions, Ryan, and I think they really speak to the movement in our field and the great success that we've had integrating systemic therapy, particularly immunotherapy, into our treatment paradigms. And so, before answering your question directly, I would add even a little bit more color, which is to note that over the last few years, we've additionally seen the development of adjuvant therapy into stages of melanoma that, historically speaking, were considered low-risk, and medical oncologists might not even see the patient. To that, I'm speaking specifically about the stage 2B and 2C approvals for adjuvant anti-PD-1 with pembrolizumab or nivolumab. So this has been an emerging complication.  Classically, patients are diagnosed with melanoma by either their primary care doctor or a dermatologist. Again, classically, the next step was referral to a surgeon who had removed the primary lesion, with discussion around nodal evaluation as well. And that paradigm has really changed now, where I think integration of medical oncology input early on in the evaluation of the appropriate treatment plan for patients with melanoma is quite a pressing issue now, both because we have FDA approvals for therapeutics that can reduce risk of recurrence, and whether or not to pursue those makes a big difference to the patient for discussion early on.  And, moreover, the use of systemic therapies now, prior to surgery, of course, then, of course, requires the involvement of medical oncology. And just for an emphasis point on this, it's classically the case, for good reason, that surgeons complete their surgery and then feel confident to tell the patient, “Well, we got it all, and you're just in really good shape.” And while I understand where that's coming from, that often leaves aside the risk of recurrence. So you can have the most perfect surgery in the world and yet still be at very high risk of recurrence. And so it's commonly the case that we get patients referred to us after surgery who think they're just in totally good shape, quite surprised to find out that, in fact, they might have a 20% to 50% risk of recurrence. And so that's where this multidisciplinary integration for patient management really does make a big difference.  And so I would really emphasize the point you were making before, which is that we need multidisciplinary teams of med onc with derm, with surgery early on, to discuss “What are the treatment plans going to be for patients?” And that's true for neoadjuvant therapy, so, for palpable stage 3, where we might give checkpoint inhibitors or combinations before surgery. But it's true even in any reasonably high-risk melanoma, and I would argue in that state, anything more than stage 1 should be discussed as a group, because that communication strategy with the patient is so important from first principles, so that they have an expectation of what it's going to look like as they are followed out over time. And so we're emphasizing this point because I think it's mostly the case at most hospitals that there isn't a cutaneous oncology disease management meeting, and I think there needs to be.  It's important to point out that usually the surgeons that do this kind of surgery are actually either the GI surgeons who do colon cancer or the breast surgeons. And so, given that melanoma, it's not the most common kind of cancer, it could easily be integrated into the existing disease review groups to review these cases. And I think that's the point we really want to emphasize now. I think we're not going to belabor the data so much, but there are enormous advantages to either perioperative or adjuvant systemic therapy in melanoma. We're talking about risk reduction of more than 50%, 50-75% risk reduction. It's essential that we make sure we optimally offer that to patients. And, of course, patients will choose what they think is best for their care. But we need to message to them in a way that they can understand what the risks and benefits of those treatments are and then are well set up to understand what that treatment might look like and what their expectations would be out over time.  So I think this is a great art of medicine place to start. Instead of belaboring just the details of the trial to say, let's think about how we take care of our patients and how we communicate with them on first principles so that we can make the most out of the treatments that we do have available. Dr. Ryan Augustin: That's great, Jason. Very insightful points. Thank you.  So, shifting gears now, I'd also like to ask you a little bit about TIL therapy in melanoma. So our listeners will be aware that TIL is a promising new approach for treating advanced melanoma and leverages the power of a patient's cytotoxic T cells to attack cancer cells. While we've known about the potential of this therapy for some time, based on pioneering work at the NCI, this therapy is now FDA approved under the brand AMTAGVI (Lifileucel) from Iovance Biotherapeutics, making it the first cellular therapy to be approved for a solid tumor. Now, I know TIL therapy has been administered at your institution, Jason, for several years now, under trial status primarily for uveal melanoma using an in-house processing. But for many cancer centers, the only experience with cellular therapy has come under the domain of malignant hematology with CAR T administration. At our institution, for example, we have only recently started administering TIL therapy for melanoma, which has required a tremendous multidisciplinary effort among outpatient oncology, critical care, and an inpatient hematology service that has expertise in cytokine release syndrome.  Jason, where do you see TIL therapy fitting into the metastatic space? Which patients do you think are truly candidates for this intensive therapy? And what other practical or logistical considerations do you think we should keep in mind moving forward? Dr. Jason Luke: Well, thanks for raising this. I think the approval of lifileucel, which is the scientific name for the TIL product that's on the market now. It really is a shift, a landscape shift in oncology, and we're starting in melanoma again, as seems to be commonly the case in drug development. But it's really important to understand that this is a conceptually different kind of treatment, and therefore, it does require different considerations. Starting first with data and then actualization, maybe secondarily, when we see across the accelerated approval package that led to this being available, we quote patients that the response rate is likely in the range of 30%, maybe slightly lower than that, but a meaningful 25% to 30% response rate, and that most of those patients that do have response, it seems to be quite durable, meaning patients have been followed up to four years, and almost all the responders are still in response. And that's a really powerful thing to be able to tell a patient, particularly if the patient has already proceeded through multiple lines of prior standard therapy. So this is a very, very promising therapy.  Now, it is a complicated therapy as well. And so you highlighted that to do this, you have to have a tumor that's amenable for resection, a multidisciplinary team that has done a surgery to remove the tumor, sent it off to the company. They then need to process the TIL out of the tumor and then build them up into a personalized cell product, bring it back, you have to lympho-deplete the patient, re-introduce this TIL. So this is a process that, in the standard of care setting under best circumstances, takes roughly six weeks. So how to get that done in a timely fashion, I think, is evolving within our paradigms. But I think it is very important for people who practice in settings where this isn't already available to realize that referring patients for this should be a strong consideration. And thinking about how you could build your multidisciplinary team in a way to be able to facilitate this process, I think is going to be important, because this concept of TIL is relevant to other solid tumors as well. It's not approved yet in others, but we kind of assume eventually it probably will be. And so I think, thinking through this, how could it work, how do you refer patients is very important.  Now, coming back to the science, who should we treat with this? Well, of course, it's now an air quotes “standard of care option”, so really it ought to be available to anybody. I will note that currently, the capacity across the country to make these products is not really adequate to treat all the patients that we'd want. But who would we optimally want to treat, of course, would be people who have retained a good performance status after first line therapy, people who have tumors that are easily removable and who have not manifested a really rapid disease progression course, because then, of course, that six-week timeline probably doesn't make sense. The other really interesting data point out of the clinical trials so far is it has looked like the patients who got the least amount of benefit from anti-PD-1 immunotherapy, in other words, who progressed immediately without any kind of sustained response, those patients seem to have the best response to TILs, and that's actually sort of a great biomarker. So, this drug works the best for the population of patients where checkpoint inhibitors were not effective. And so as you think about who those patients might be in your practice, as you're listening, I think prioritizing it for primary progression on anti PD-1, again and giving it ahead thought about how would you get the patient through this process or referred to this process very quickly is really important because that lag time is a problem. Patients who have melanoma tend to progress reasonably quickly, and six weeks can be a long time in melanoma land. So, thinking ahead and building those processes is going to be important moving into the future Dr. Ryan Augustin: Definitely appreciate those practical considerations. Jason, thank you.  Moving on to our final topic, I was hoping to discuss the use of immune cell engagers in melanoma. So, similar to CAR T therapy, bispecific T-cell engagers, or BiTEs, as they're commonly known, are standard of care in refractory myeloma and lymphoma. But these antibodies engaging CD-3 on T cells and a tumor specific antigen on cancer cells are relatively new in the solid tumor space. Tarlatamab, which is a DLL-3 and CD-3 bispecific antibody, was recently approved in refractory small cell lung cancer, and, of course, tebentafusp, an HLA-directed CD-3 T cell engager was approved in uveal melanoma in 2022. Both T and NK cell engaging therapies are now offering hope in cancers where there has historically been little to offer. However, similar to our discussion with TIL therapy, bispecifics can lead to CRS and neurotoxicity, which require considerable logistical support and care coordination.  Jason, I was wondering if you could briefly discuss the current landscape of immune cell engagers in melanoma and how soon we may see these therapies enter the treatment paradigm for cutaneous disease. Dr. Jason Luke: I think it is an exciting, novel treatment strategy that I think we will only see emerge more and more. You alluded to the approval of tebentafusp in uveal melanoma, and those trials were, over the course of a decade, where those of us in solid tumor land learned how to manage cytokine release syndrome or the impact of these C3 bispecifics, in a way that we weren't used to. And what I'll caution people is that CRS, as this term, it sounds very scary because people have heard of patients that, of course, had difficult outcomes and hematological malignancies, but it's a spectrum of side effects. And so, when we think about tebentafusp, which is the approved molecule, really what we see is a lot of rash because GP100, the other tumor antigen target, is in the skin. So, patients get a rash, and then people do get fevers, but it's pretty rare to get more than that. So really what you have to have is the capacity to monitor patients for 12 hours, but it's really not more scary than that. So it really just requires treating a few people to kind of get used to these kinds of symptoms, because they're not the full-on ICU level CRS that we see with, say, CAR T-cells.  But where is the field going? Well, there's a second CD3 bispecific called brenetafusp that targets the molecule PRAME, that's in a phase 3 clinical trial now for frontline cutaneous melanoma. And tebentafusp is also being evaluated in cutaneous melanoma for refractory disease. So, it's very possible that these could be very commonly used for cutaneous melanoma, moving into, say, a two-to-four-year time horizon. And so therefore, getting used to what are these side effects, how do you manage them in an ambulatory practice for solid tumor, etc., is going to be something everyone's going to have to learn how to deal with, but I don't think it should be something that people should be afraid of.  One thing that we've seen with these molecules so far is that their kinetics of treatment effect do look slightly different than what we see with more classic oncology therapies. These drugs have a long-term benefit but doesn't always manifest as disease regression. So, we commonly see patients will have stable disease, meaning their tumor stops growing, but we don't see that it shrank a lot, but that can turn into a very meaningful long-term benefit. So that's something that we're also, as a community, going to have to get used to. It may not be the case we see tumors shrink dramatically upfront, but rather we can actually follow people with good quality- of-life over a longer period of time.  Where is the field going? You mentioned tarlatamab in small cell lung cancer, and I think we're only going to see more of these as appropriate tumor antigens are identified in different tumors. And then the other piece is these CD3 engagers generally rely upon some kind of engagement with a T cell, whether CD3 engagers, and so they can be TCR or T-cell receptor-based therapies, although they can be also SCFV-based. But that then requires new biomarkers, because TCR therapy requires HLA restriction. So, understanding that now we're going to need to profile patients based on their germline in addition to the genomics of the tumor. And those two things are separate. But I would argue at this point, basically everybody with cutaneous melanoma should be being profiled for HLA-A(*)0201, which is the major T-cell receptor HLA haplotype that we would be looking for, because whether or not you can get access immediately to tebentafusp, but therefore clinical trials will become more and more important.  Finally, in that T-cell receptor vein, there are also T cell receptor-transduced T cells, which are also becoming of relevance in the oncology community and people listening will be aware in synovial sarcoma of the first approval for a TCR-transduced T cell with afamitresgene autoleucel. And in melanoma, we similarly have TCR-transduced T cells that are coming forward in clinical trials into phase 3, the IMA203 PRAME-directed molecule particularly. And leveraging our prior conversation about TILs, we're going to have more and more cellular based therapies coming forward, which is going to make it important to understand what are the biomarkers that go with those, what are the side effect profiles of these, and how do you build your practice in a way that you can optimally get your patients access to all of these different treatments, because it will become more logistically complicated, kind of as more of these therapies come online over the next, like we said, two to four years kind of time horizon. So, it's very exciting, but there is more to do, both logistically and scientifically. Dr. Ryan Augustin: That's excellent. Thanks, Jason, and thank you so much for sharing your great insight with us today on the ASCO Daily News Podcast. Dr. Jason Luke: Thanks so much for the opportunity. Dr. Ryan Augustin: And thank you to our listeners for your time today. You will find links to the abstracts discussed today in the transcript of this episode, and you can follow Dr. Luke on X, formerly known as Twitter, @jasonlukemd. And you can find me, @RyanAugustinMD. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: @ryanaugustinmd Dr. Jason Luke @jasonlukemd   Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn   Disclosures: Dr. Ryan Augustin: No relationships to disclose Dr. Jason Luke: Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof) Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

In this journal club episode, my guest is Dr. Peter Attia, M.D., a Stanford and Johns Hopkins-trained physician focusing on healthspan and lifespan and the host of The Drive podcast. We each present a peer-reviewed scientific paper chosen because it contains novel, interesting, and actionable data. First, we discuss a paper on how bright light exposure at sunrise and throughout the day and dark exposure at night independently improve mental health and can offset some of the major symptoms of mental health disorders such as depression and anxiety. Then, we discuss an article that explores a novel class of immunotherapy treatments to combat cancer. We also discuss some of the new data on low-calorie sweeteners and if they are safe. This episode should be of interest to listeners curious about maximizing their vitality and longevity and to anyone seeking science-supported ways to improve mental health and lifespan. For show notes, including referenced articles and additional resources, please visit hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Eight Sleep: https://www.eightsleep.com/huberman BetterHelp: https://betterhelp.com/huberman Joovv: https://joovv.com/huberman LMNT: https://drinklmnt.com/huberman Momentous: https://livemomentous.com/huberman Timestamps (00:00:00) Dr. Peter Attia, Journal Club (00:02:40) Sponsors: Eight Sleep, BetterHelp & Joovv (00:07:14) Light, Dark & Mental Health; Retina (00:11:16) Outdoor vs. Indoor Light, Cataracts, Sunglasses (00:16:17) Tools: Sunrise & Sunsets, Circadian Rhythm; Midday Light (00:24:55) Tools: Night & Light Exposure; Waking Before Sunrise (00:31:05) Article #1, Light/Dark Exposure & Mental Health (00:36:50) Sponsor: AG1 (00:38:18) Odds Ratio, Hazard Ratio (00:45:43) Night vs. Daylight Exposure, Mental Health Disorders (00:51:35) Major Depression & Light Exposure; Error Bars & Significance (00:59:15) Sponsor: LMNT (01:00:39) Prescriptions; Environmental & Artificial Light; Red Lights (01:08:14) Nighttime Light Exposure; Sleep Trackers & Belief Effects (01:13:54) Light Directionality, Phone, Night (01:17:21) Light Wavelengths & Sensors; Sunglasses (01:20:58) Hawthorne Effect, Reverse Causality, Genetics (01:26:26) Artificial Sweeteners, Appetite (01:31:16) Natural Light Cycles, Circadian Rhythm & Mental Health (01:39:53) Article #2, Immune System & Cancer (01:43:18) T-Cell Activation; Viruses (01:50:41) Autoimmunity; Cancer & Immune System Evasion (02:00:09) Checkpoint Inhibitors, CTLA-4 (02:06:45) Anti-CTLA-4 Study Drug (Ipilimumab), Melanoma (02:12:07) Patient Population, Randomization, GP100 (02:18:09) Response Rate (02:22:52) Overall Survival & Response (02:28:38) Median Survival vs. Overall Survival, Drug Development (02:35:45) Gender & Dose (02:40:32) Adverse Events; Autoimmunity (02:46:42) Pancreatic Cancer; Aging & Immune System Health (02:53:57) Melanoma; Lynch Syndrome, Keytruda (02:58:43) Immunotherapy & Cancer Treatment; Melanoma Risk (03:06:26) Zero-Cost Support, Spotify & Apple Reviews, YouTube Feedback, Sponsors, Momentous, Social Media, Neural Network Newsletter Disclaimer

本集節目由【BenQ】贊助播出 BenQ微型投影機GV31、GP100， 標榜三大特點「好畫面，好聲音，好方便」 真的非常適合懶人、又想懂得享受生活、欣賞電影的消費者 一機在手，輕鬆擁有奢華輕劇院 6/15~7/17 全球首賣，限時優惠，最高現省$8,990元 活動傳送門 >> https://benqurl.biz/3J0CgZ7  #好畫面。小機身也有精準色彩  BenQ 獨家 CinematicColor 色彩管理技術，精準呈現 Rec.709 國際標準色域。 #好聲音。2.1聲道的震撼立體音場 內建2.1聲道、立體聲喇叭，特過獨立的 DSP 數位音效處理晶片、 treVolo 心理聲學調校，設定出適合觀看電影、遊戲、運動賽事等不同模式。 #好方便。一轉投影天花板，一線直連Switch 獨特機身設計、方便你直接投影天花板*；以及克服空間障礙，可自動側投影*、修正方正大畫面。Type-C 連接埠可充電與傳輸影像，Nintendo Switch可直接連接使用。 * GV31方可直接投影天花板；GP100 方可左右自動側投影

The winners of this year's GP100 include the 2021 Game Changers: products that represent a massive shift in their respective categories. Episode Navigation:00:00 – What Is a Game Changer?06:41 – I/O MAG Imprint 3D Goggle from Smith13:15 – Whoop Any-Wear19:15 – KYX Sneaker Rental27:46 – Bose SoundControl Hearing Aids37:47 – Dyson V15 Detect44:32 – Fellow Drops51:55 – Apple MacBook Pros57:50 – Syng Cell Alpha Speaker1:04:11 – Rivian R1T1:11:11 – Bremont ENG300 MovementFeatured and Related:The 2021 GP100The 10 Best New Tech Products of the YearThe 10 Best New Audio Products of the YearThe 10 Best New Home Products of the YearThe 10 Best New Food & Drink Products of the YearThe 10 Best New Wellness Products of the YearThe 10 Best New Style Products of the YearThe 10 Best Fitness Products of 2022The 10 Best Outdoor Products of 2022

요한복음 (John) 20:19-23 평강과 성령으로 보냄받은 공동체 Community of Faith Sent with Peace and the Spirit"

Suggested reading for the concealed carrier. https://sandiegocountygunowners.com/ccw-lifestyle-series-9-suggested-reading-for-concealed-carriers/ GEAR REVIEW: It's revolver day at GSR.  Joe shares his review of the Ruger GP100 Match Champion. The crew reviews the pandemonium we experienced recently with the protests and riots. How do you effect positive change when there's no leadership and well defined policy changes? Stump My Nephew! What's the difference between rimfire and centerfire ammunition? -- The right to self-defense is a basic human right. Gun ownership is an integral part of that right. If you want to keep your rights defend them by joining San Diego County Gun Owners (SDCGO),  Orange County Gun Owners (OCGO) in Orange County, San Bernardino County Gun Owners (SBCGO) in San Bernardino County or Riverside County Gun Owners (RCGO) in Riverside. Support the cause by listening to Gun Sports Radio live on Sunday afternoon or on the internet at your leisure Join the fight and help us restore and preserve our second amendment rights. Together we will win. https://www.gunsportsradio.com https://www.sandiegocountygunowners.com https://orangecountygunowners.com/  https://sanbernardinocountygunowners.org/ https://riversidecountygunowners.com/  https://www.firearmspolicy.org/ https://www.gunownersca.com/ https://gunowners.org -- Show your support for Gun Sports Radio sponsors! https://FirearmsLegal.com  https://www.ccwusa.com  https://www.firearmslegal.com  http://www.kalikey.com https://www.primeres.com/alpine  https://dillonlawgp.com https://www.aosword.com  https://www.thegunrangesandiego.com  https://www.uslawshield.com 

On this week’s episode, Chad reviews the Lucid Optic’s Litl Mo micro red dot optic. The crew talks about the Ruger Custom Shop GP 100 in 9mm, SwampFox’s new flagship optic – the Warhawk in 5-25×56, and Faxon Firearms Bantam 9mm PCC pistol. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

On this week's episode, Chad reviews the Lucid Optic’s Litl Mo micro red dot optic. The crew talks about the Ruger Custom Shop GP 100 in 9mm, SwampFox’s new flagship optic – the Warhawk in 5-25×56, and Faxon Firearms Bantam 9mm PCC pistol. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

On this week’s episode, Chad reviews the Lucid Optic’s Litl Mo micro red dot optic. The crew talks about the Ruger Custom Shop GP 100 in 9mm, SwampFox’s new flagship optic – the Warhawk in 5-25×56, and Faxon Firearms Bantam 9mm PCC pistol. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

On this week's episode, we discuss 3 different handguards – The Odin Works Rune, The STNGR VLCN, and the Timber Creek UltraLight  Enforcer. Plus we talk about the new GP 100 8 shot 357 from Ruger. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

On this week’s episode, we discuss 3 different handguards – The Odin Works Rune, The STNGR VLCN, and the Timber Creek UltraLight  Enforcer. Plus we talk about the new GP 100 8 shot 357 from Ruger. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

On this week's episode, we discuss the Ruger GP100 7 sho​t in 357 Magnum, Anderson 224 Valkerie upper, ​and Merrisa from​ Bishop Firearms ​helps us discuss their ​458 SOCOM Hunter​ bolt action rifle​. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

On this week’s episode, we discuss the Ruger GP100 7 sho​t in 357 Magnum, Anderson 224 Valkerie upper, ​and Merrisa from​ Bishop Firearms ​helps us discuss their ​458 SOCOM Hunter​ bolt action rifle​. For all the show notes and back episodes, head over to firearmsradio.tv/gun-and-gear-review-podcast

PC Perspective Podcast #436 - 02/09/17 Join us for ECS Mini-STX, NVIDIA Quadro, AMD Zen Arch, Optane, GDDR6 and more! You can subscribe to us through iTunes and you can still access it directly through the RSS page HERE. The URL for the podcast is: http://pcper.com/podcast - Share with your friends! iTunes - Subscribe to the podcast directly through the iTunes Store (audio only) Video version on iTunes Google Play - Subscribe to our audio podcast directly through Google Play! RSS - Subscribe through your regular RSS reader (audio only) Video version RSS feed MP3 - Direct download link to the MP3 file Hosts: Ryan Shrout, Allyn Malventano, Ken Addison, Josh Walrath, Jermey Hellstrom Program length: 1:32:21 Podcast topics of discussion: Join our spam list to get notified when we go live! Patreon Week in Review: 0:08:07 Mini-STX Build: ECS H110S-2P and SilverStone VT01 Review 0:16:20 New NVIDIA Quadro offerings include GP100 with 16GB HBM2 0:25:37 AMD Details Low Level Aspects of Zen Arch News items of interest: 0:34:45 EVGA's new EVGA CLC 120 and 280 Liquid Coolers 0:39:10 Yes Acer was the company that released the XR382CQK bmijqphuzx Display 0:45:45 Report: AMD Ryzen Performance in Ashes of the Singularity Benchmark 0:46:45 Intel Has Started Shipping Optane Memory Modules 0:52:00 Micron Planning To Launch GDDR6 Graphics Memory In 2017 0:58:45 Windows 10 Game Mode Gets Benchmarked, Still Needs Work 1:02:45 Palit Introduces Fanless GeForce GTX 1050 Ti KalmX GPU 1:04:10 Logitech Announces BRIO Webcam: 4K and HDR 1:07:30 Intel's Atom C2xxx processors may just make like a banana and split 1:11:20 Star Wars Humble Bundle III; better than the movie! 1:14:00 Zen Price Points Leaked Hardware/Software Picks of the Week Jeremy: Lazarus saves my bacon frequently Josh: Monoprice eBay for i7 7700K Allyn: Low cost OBD II scanner http://pcper.com/podcast http://twitter.com/ryanshrout and http://twitter.com/pcper Closing/outro Mentioned: Drones at super bowl returning to programmers video Subscribe to the PC Perspective YouTube Channel for more videos, reviews and podcasts!!

Recorded with fans in London, it’s GP100 starring Finn Bálor, Bayley and some very special surprise guests! See acast.com/privacy for privacy and opt-out information.

Full thoughts on SmackDown Live’s latest PPV, WWE TLC + build up for GP100 See acast.com/privacy for privacy and opt-out information.

WWE Cruiserweight talent Noam Dar interview, Survivor Series predictions plus big announcement for GP100 See acast.com/privacy for privacy and opt-out information.

Xavier Woods talks video games & WWE 2K17, RAW & SmackDown recaps + big GP100 news! See acast.com/privacy for privacy and opt-out information.

Welcome to the We Like Shooting show, Episode 41.  This week we’ll talk about Clear Ballistics, Grips for a GP100, FACOG’s, Homak Gun Safes, CMC triggers and carbon fiber suppressors.